TEVA-LISINOPRIL/HCTZ (TYPE P) TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE

Available from:

TEVA CANADA LIMITED

ATC code:

C09BA03

INN (International Name):

LISINOPRIL AND DIURETICS

Dosage:

10MG; 12.5MG

Pharmaceutical form:

TABLET

Composition:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG; HYDROCHLOROTHIAZIDE 12.5MG

Administration route:

ORAL

Units in package:

30/100

Prescription type:

Prescription

Therapeutic area:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product summary:

Active ingredient group (AIG) number: 0222417003; AHFS:

Authorization status:

APPROVED

Authorization date:

2010-12-08

Summary of Product characteristics

PRODUCT MONOGRAPH
PR
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin Converting Enzyme Inhibitor/Diuretic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 169889
Date of Preparation:
November 26, 2010
Date of Revision:
January 21, 2014
TEVA-LISINOPRIL/HCTZ (TYPE P) Tablets
2
PRODUCT MONOGRAPH
Pr
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin-Converting Enzyme Inhibitor/Diuretic
ACTION AND CLINICAL PHARMACOLOGY
TEVA-LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide
tablets) combines the
action of an angiotensin-converting enzyme (ACE) inhibitor,
lisinopril, and a diuretic,
hydrochlorothiazide.
LISINOPRIL
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum potassium. In patients
treated with lisinopril plus a
thiazide diuretic, there was essentially no change in serum potassium
(see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
LISINOPRIL
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of li